Interleukin-2 receptor blockade in cardiac transplantation: Influence of HLA-DR locus incompatibility on treatment efficacy

Transplantation

Volumn 75, Issue 6, 2003, Pages 781-787

  Lietz, Katherine ^a   John, Ranjit ^a   Beniaminovitz, Ainat ^a   Burke, Elizabeth M ^a   Suciu Foca, Nicole ^a   Mancini, Donna M ^a   Edwards, Niloo M ^a   Itescu, Silviu ^a,b  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DACLIZUMAB; HLA ANTIBODY; HLA DR ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID;

ADULT; ALLOIMMUNITY; ARTICLE; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEMODYNAMICS; HISTOINCOMPATIBILITY; HUMAN; IMMUNOMODULATION; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TISSUE DONORS;

EID: 0037468734     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000055214.63049.3C     Document Type: Article

References (33)

1. Itescu S, Tung T, Burke E, et al. An immunological algorithm to predict risk of high-grade rejection in cardiac transplant recipients. Lancet 1998; 352: 263-270.
2. Kormos R, Armitage J, Wolyn T, et al. Graft atherosclerosis: effects of cellular rejection and human lymphocyte antigen. J Heart Lung Transplant 1992; 11(3): S104-S110.
3. Kerman RH, Kimball P, Scheinen S, et al. The relationship among donor-recipient HLA mismatches, rejection, and death from coronary artery disease in cardiac transplant recipients. Transplantation 1994; 57(6); 884-888.
4. Smith JD, Rose ML, Pomerance A, et al. Reduction of cellular rejection and increase in longer-term survival after heart transplantation after HLA-DR matching. Lancet 1995; 346: 1318-1322.
5. Constanzo-Nordin MR. Cardiac allograft vasculopathy: Relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992; 11: S90-103.
6. Suciu-Foca N, Reed E, Marboe C, et al. Role of anti-HLA antibodies in heart transplantation. Transplantation 1991; 51: 716-724.
7. Hess M, Hastillo A, Mohanakumar T, et al. Accelerated atherosclerosis in cardiac transplantation: Role of cytotoxic B cell antibodies and hyperlipidemia. Circulation 1983; 68: 94-101.
8. Rose EA, Pepino P, Barr M, et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992; S120-123.
9. Rizeq M, Masek MA, Billingham ME. Acute rejection: Significance of elapsed time after transplantation. J Heart Lung Transplant 1994; 13(5); 862-868.
10. Winters GL, Loh E, Schoen FJ. Natural history of focal moderate cardiac allograft rejection: Is treatment warranted. Circulation 1995; 91: 1975-1980.
11. White JA, Guirandon C, Pfluglelder PW, Kostuk WJ. Routine surveillance myocardial biopsies are unnecessary beyond one year after heart transplantation. J Heart Lung Transplant 1995; 14: 1052.
12. Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: A multiinstitutional, multivariable analysis. Cardiac Transplant Research Database Group. J Heart Lung Transplant 1990; 9: 77.
13. Liu Z, Colovai AI, Tugulea S, et al. Indirect recognition of donor HLA-DR peptides in organ allograft rejection. J Clin Invest 1996; 98: 1150-1157.
14. Tugulea S, Ciubotariu R, Colovai AI, et al. New strategies for early diagnosis of heart allograft rejection. Transplantation 1997; 64: 842-847.
15. Ciubotariu R, Liu Z, Colovai AI, et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998; 101: 398-405.
16. Arnold B, Schonrich G, Hammerling GJ. Multiple levels of peripheral tolerance. Immunol Today 1993; 14: 338-344.
17. Kabelitz D. Apoptosis, graft rejection, and transplantation tolerance. Transplantation 1998; 65: 869-875.
18. Norman DJ, Kahana L, Stuart FP Jr, et al. A randomized clinical trial of induction therapy with OKT3 in kidney transplantation. Transplantation 1993; 55: 44-50.
19. Larsen CP, Elwood ET, Alexander DZ, et al. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 1996; 381: 434-439.
20. Woodward JE, Qin L, Chavin KD, et al. Blockade of multiple costimulatory receptors induces hyporesponsiveness: Inhibition of CD2 plus CD28 pathways. Transplantation 1996; 62: 1011-1016.
21. Hancock WW, Buelow R, Sayegh MH, Turka LA. Antibody-induced transplant arteriosclerosis is prevented by graft expression of anti-oxidant and anti-apoptotic genes. Nat Med 1998; 4(12): 1392-1396.
22. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999; 5(6): 686-693.
23. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems. The differential activation of Th2-like effector cells in peripheral tolerance. Transplantation 1992; 53(6): 1281-1294.
24. Thai NL, Fu F, Qian S, et al. Cytokine mRNA profiles in mouse orthotopic liver transplantation. Graft rejection is associated with augmented TH1 function. Transplantation 1995; 59(2): 274-281.
25. Vincenti F, Kirkman R, Light S, et al. Interleukin 2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161-165.
26. Billingham ME. Dilemma of variety of histopathologic grading systems for acute cardiac allograft rejection by endomyocardial biopsy. J Heart Transplant 1990; 9: 272-276.
27. Wei LJ, Lin DY, Weissfeld L. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989; 84: 1065-1073.
28. Johnson MR, Mullen GM, O'Sullivan EJ, et al. Risk/benefit ratio of perioperative OKT3 in cardiac transplantation. Am J Cardiol 1994; 74(3): 261-266.
29. Hakimi J, Chizzonite R, Luke DR, et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991; 147: 1352-1359.
30. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation. 2001; 7: 1282-1287.
31. Steiger J, Nickerson PW, Steurer W, et al. IL-1 knockout recipient mice reject islet cell allografts. J Immunol 1995; 55: 489-498.
32. Manfro RC, Roy-Chaudhury P, Zheng XX, et al. Inerleukin-15 gene transcripts are present in rejecting islet allografts. Transpl Proc 1997; 29: 1077-1078.
33. Baan CC, van Gelder T, Balk AH, et al. Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection. Transplantation 2000; 69: 331-336.